Talk:Olanzapine
Jump to navigation
Jump to search
initial draft. This will contain a myriad of information and will be formatted later :) --Corticosteroid (talk) 22:58, 20 October 2017 (CEST)
Olanzapine, first branded as Zyprexa, is a widely-used antipsychotic substance of the thienobenzodiazepine chemical class. It produces sedating and neuroleptic effects when administered. Olanzapine can be given by mouth and can also be injected into a muscle. Olanzapine might be useful as a trip aborter, especially for stimulants, as it blocks the action of dopamine. [citation needed]
Chemistry
Olanzapine is a thienobenzodiazepine. It includes a piperazine moiety at R4.
Pharmacology
Olanzapine is known to cause weight gain and induce diabetes mellitus type 2 more frequently than other antipsychotics. However, it is less likely to produce tardive dyskinesia or an extrapyramidal reaction. It appears to be an effective treatment for schizophrenia.[1]
Subjective effects
Physical effects
-
- Hunger - This often happens over a course of treatment and not with one use.
- Sedation - This effect is more often uncomfortably tiring than relaxing.
- Salivation
- Muscle relaxation
- Motor control loss
- Dizziness
- Perception of bodily heaviness
- Headaches
- Extrapyramidal symptoms
Cognitive effects
-
- Anxiety suppression - This is mediated by olanzapine's antidopaminergic, antiadrenergic, and antiserotonergic action rather than GABA-related activity.
- Emotionality suppression - Olanzapine dulls and suppresses emotions.
- Focus suppression or enhancement - This often depends on the mental state of the individual.
- Decreased libido
- Sleepiness
- Cognitive euphoria - This effect is extremely rare. Olanzapine is often a dulling, "boring" pharmaceutical.
- Cognitive dysphoria - This often includes a sense of boredom or depression accompanied by uncomfortable sedation.
not the crème de là crème
- (doses:
- Light: 2.5 mg
- Medium: 5 to 7.5 mg
- Heavy: 10 mg
- Strong: 10 mg +)
External links
References
- ↑ Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., ... & Kissling, W. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet, 382(9896), 951-962.